Bristol-Myers concedes a PhIII lung cancer flop for Opdivo as competition heats up in SCLC
Bristol-Myers Squibb $BMY has run into another dead end in exploring the lung cancer market.
The big biotech reported that its Phase III study of Opdivo failed the CheckMate-331 study, unable to beat the standard of care for treating second-line small cell lung cancer.
We don’t know yet just what the data are, just that the readout doesn’t measure up to a win. And the setback comes just months after Roche’s combo using Tecentriq and chemo won out on first-line cases of SCLC, a tough field that accounts for about 15% of the overall lung cancer market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.